Immunocore reports 29% ORR and 71% disease control rate for brenetafusp in Phase 1/2 study

Immunocore announced data from its Phase 1/2 study of brenetafusp showing a 29% overall response rate and 71% disease control rate.

Detected & updated continuously · Source: Nebula